Innova Therapeutics, a biopharmaceutical company, has announced that it has completed the acquisition of Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. “The acquisition of Enci Therapeutics and IVT-8086 marks a pivotal step for Innova Therapeutics in our commitment to pioneering novel cancer therapies,” said Robert Ryan, Ph.D., Chief Executive Officer of Innova Therapeutics. “This cancer treatment platform has the highest potential in my view to change the paradigm of treatment of patients with many types of solid and hematological cancers, resulting in long term survival,” said Dr. Ryan.
Read the full article: Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition //
Source: https://www.prnewswire.com/news-releases/innova-therapeutics-to-advance-novel-cancer-treatment-with-enci-therapeutics-acquisition-302624767.html